Generic Name and Formulations:
Iron (as sodium ferric gluconate complex in sucrose) 12.5mg/mL; soln for IV inj or infusion; contains benzyl alcohol.
Company:
Sanofi Aventis

Select therapeutic use: Anemias
Indications for FERRLECIT:
Iron deficiency anemia in patients on chronic hemodialysis receiving epoetin therapy.

Adult:
Give by IV infusion (diluted) or slow IV inj (undiluted). 125mg infused over 1 hour or by slow IV inj (at a rate of up to 12.5mg/min). Minimum cumulative dose: 1g given over 8 sequential dialysis sessions; usual max: 125mg/dose.

Children:
<6 yrs: not recommended. Give by IV infusion (diluted) over 1 hour. ≥6yrs: 1.5mg/kg per dose at 8 sequential dialysis sessions; max: 125mg/dose.

Contraindications:
Anemias not caused by iron deficiency. Iron overload. Neonates.

Warnings/Precautions:
Hemoglobinopathies. Refractory anemias. Pregnancy (Cat. B). Nursing mothers.

Interactions:
May reduce absorption of concomitant oral iron preparations.

Pharmacological Class:
Hematinic.

Adverse Reactions:
Hypotension, hypertension, GI upset, chest pain, back pain, abdominal pain, pruritus, inj site reaction, headache, dizziness, syncope, fatigue, fever, cramps, dyspnea, tachycardia; rare: hypersensitivity reactions.

How Supplied:
Ampules (5mL)—10